Brief: Innate Pharma H1 Operating Loss Widens To EUR 25.4 Mln

Innate Pharma SA

15/09/2021 06:16

Sept 15 (Reuters) - INNATE PHARMA SA  IPH.PA :
    * REPORTS FIRST HALF 2021 FINANCIAL RESULTS AND BUSINESS
UPDATE
    * FIRST DATA SET FROM LACUTAMAB TELLOMAK TRIAL DEMONSTRATED
ENCOURAGING 35% OVERALL GLOBAL RESPONSE RATE, INCLUDING SKIN
IMPROVEMENT IN PATIENTS WITH MYCOSIS FUNGOIDES THAT EXPRESS
KIR3DL2
    * NEW PRE-CLINICAL DATA PRESENTED FROM NEXT-GENERATION NK
CELL
ENGAGER PLATFORM, ANKET™, HIGHLIGHTED ROBUST ANTI-TUMOR EFFICACY
ACROSS SEVERAL IN VIVO TUMOR MODELS AND MANAGEABLE SAFETY
PROFILE
    * CASH POSITION OF EUR 159.4 MILLION AS OF JUNE 30, 2021
    * REVENUE AND OTHER INCOME AMOUNTED TO EUR 15.7M IN FIRST
HALF OF
2021 (EUR 36.7M IN FIRST HALF OF 2020)
    * OPERATING EXPENSES ARE EUR 41.1M IN FIRST HALF OF 2021
(EUR
46.0M IN FIRST HALF OF 2020)
    * A NET LOSS OF EUR 23.7M FOR FIRST HALF OF 2021 (NET LOSS
OF EUR
10.3M FOR FIRST HALF OF 2020)
    * H1 OPERATING LOSS EUR 25.4 MILLION VERSUS LOSS OF EUR 8.3
MILLION YEAR AGO
    * PROGRESS WAS MADE IN IPH6101/SAR443579 COLLABORATION WITH
SANOFI, RESULTING IN DECISION ANNOUNCED IN JANUARY 2021 THAT
SANOFI WILL TRANSITION IPH6101/SAR443579 INTO INVESTIGATIONAL
NEW DRUG (IND)-ENABLING STUDIES
    * MONALIZUMAB (ANTI-NKG2A ANTIBODY), PARTNERED WITH
ASTRAZENECA:
COMPANY EXPECTS TO PUBLISH DATA THIS YEAR FROM PHASE 2 EXPANSION
COHORT

Source text for Eikon:  ID:nNDL9R2Zw5 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))